收费全文 | 120311篇 |
免费 | 7537篇 |
国内免费 | 469篇 |
耳鼻咽喉 | 1494篇 |
儿科学 | 3109篇 |
妇产科学 | 2122篇 |
基础医学 | 15351篇 |
口腔科学 | 2212篇 |
临床医学 | 12400篇 |
内科学 | 23979篇 |
皮肤病学 | 1711篇 |
神经病学 | 12099篇 |
特种医学 | 4835篇 |
外国民族医学 | 15篇 |
外科学 | 19275篇 |
综合类 | 1263篇 |
一般理论 | 137篇 |
预防医学 | 9688篇 |
眼科学 | 2805篇 |
药学 | 7799篇 |
中国医学 | 146篇 |
肿瘤学 | 7877篇 |
2023年 | 540篇 |
2022年 | 924篇 |
2021年 | 2384篇 |
2020年 | 1499篇 |
2019年 | 2345篇 |
2018年 | 2839篇 |
2017年 | 2051篇 |
2016年 | 2241篇 |
2015年 | 2597篇 |
2014年 | 3844篇 |
2013年 | 5312篇 |
2012年 | 8397篇 |
2011年 | 8792篇 |
2010年 | 5085篇 |
2009年 | 4599篇 |
2008年 | 7901篇 |
2007年 | 8295篇 |
2006年 | 7971篇 |
2005年 | 7682篇 |
2004年 | 7454篇 |
2003年 | 6717篇 |
2002年 | 6422篇 |
2001年 | 1533篇 |
2000年 | 1266篇 |
1999年 | 1508篇 |
1998年 | 1467篇 |
1997年 | 1158篇 |
1996年 | 946篇 |
1995年 | 852篇 |
1994年 | 740篇 |
1993年 | 707篇 |
1992年 | 852篇 |
1991年 | 828篇 |
1990年 | 734篇 |
1989年 | 658篇 |
1988年 | 664篇 |
1987年 | 615篇 |
1986年 | 584篇 |
1985年 | 579篇 |
1984年 | 546篇 |
1983年 | 432篇 |
1982年 | 468篇 |
1981年 | 407篇 |
1980年 | 351篇 |
1979年 | 314篇 |
1978年 | 290篇 |
1977年 | 269篇 |
1976年 | 227篇 |
1975年 | 219篇 |
1974年 | 234篇 |
Background
The optimal noninvasive test (NIT) for patients with diabetes and stable symptoms of coronary artery disease (CAD) is unknown.Objectives
The purpose of this study was to assess whether a diagnostic strategy based on coronary computed tomographic angiography (CTA) is superior to functional stress testing in reducing adverse cardiovascular (CV) outcomes (CV death or myocardial infarction [MI]) among symptomatic patients with diabetes.Methods
PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) was a randomized trial evaluating an initial strategy of CTA versus functional testing in stable outpatients with symptoms suggestive of CAD. The study compared CV outcomes in patients with diabetes (n = 1,908 [21%]) and without diabetes (n = 7,058 [79%]) based on their randomization to CTA or functional testing.Results
Patients with diabetes (vs. without) were similar in age (median 61 years vs. 60 years) and sex (female 54% vs. 52%) but had a greater burden of CV comorbidities. Patients with diabetes who underwent CTA had a lower risk of CV death/MI compared with functional stress testing (CTA: 1.1% [10 of 936] vs. stress testing: 2.6% [25 of 972]; adjusted hazard ratio: 0.38; 95% confidence interval: 0.18 to 0.79; p = 0.01). There was no significant difference in nondiabetic patients (CTA: 1.4% [50 of 3,564] vs. stress testing: 1.3% [45 of 3,494]; adjusted hazard ratio: 1.03; 95% confidence interval: 0.69 to 1.54; p = 0.887; interaction term for diabetes p value = 0.02).Conclusions
In diabetic patients presenting with stable chest pain, a CTA strategy resulted in fewer adverse CV outcomes than a functional testing strategy. CTA may be considered as the initial diagnostic strategy in this subgroup. (PROspective Multicenter Imaging Study for Evaluation of Chest Pain [PROMISE]; NCT01174550) 相似文献Methods: A retrospective cohort design and data from two US healthcare claims repositories were employed. The study population included patients who had non-metastatic cancer of the breast, colon/rectum, lung or ovaries, or non-Hodgkin’s lymphoma (NHL), and who received myelosuppressive chemotherapy regimens with an intermediate/high risk for FN. For each patient, the first cycle of the first course was characterized in terms of PP-CSF use and FN episodes. Crude incidence proportions for PP-CSF and FN during the first cycle were estimated by calendar quarter (2010–2016); multivariable logistic regression models were used to estimate quarter-specific adjusted mean probabilities of FN by PP-CSF use.
Results: The study population totaled 142,730 patients with breast cancer (61%), colorectal cancer (14%), NHL (11%), ovarian cancer (10%) or lung cancer (5%). PP-CSF use increased from 52% in 1Q2010 to 58% in 4Q2016; pegfilgrastim was the most commonly used agent (>96% across quarters). PP-CSF administration on the same day as chemotherapy ranged from 8 to 11% until 1Q2015, and increased to 64% by 4Q2016. Adjusted incidence proportions for FN in the first chemotherapy cycle ranged from 2.7% (95% CI: 2.3–3.0) to 3.7% (95% CI: 3.1–4.3) among those who did not receive PP-CSF, and was 2.6% (95% CI: 2.5–2.7) across quarters among those who received PP-CSF.
Conclusions: Although the use of PP-CSF is commonplace in current US clinical practice, underutilization in cancer patients receiving chemotherapy regimens with an intermediate/high risk for FN may still be an issue. Use of same-day PP-CSF increased markedly from the end of 2015, although this finding reflects (at least in part) increased uptake of pegfilgrastim delivered via an on-body injector as well as the recent change in clinical practice guidelines. Overall, patients receiving PP-CSF appear to have a lower risk of FN during the first cycle of chemotherapy. 相似文献